Table 6.

Overview of polymorphisms in genes encoding antigen processing machinery components and association with cervical neoplasia risk/survival.

Gene	Polymorphisma	Cohort	Cases (n)	Population	Distribution	Risk (OR, 95% CI); PAFb,c,d	Reference
ERAP1	ERAP1-127 (c.+380G>C rs26653)	Cervical cancer	127	Dutch	Alleles	C: 1.652 (1.106–2.467); 12.4%	[41]
			98	Javanese	Alleles	C: 0.656 (0.437–0.985)	[42]
	ERAP1-730 (c.+2188C>G; rs27044)	Cervical cancer	127	Dutch	Alleles	G: 1.685 (1.136–2.500); 13.6%	[41]
			98	Javanese	Alleles	G: 0.644 (0.431–0.962)	[42]
	ERAP1-528 (c.+1583C>T; rs30187)	Cervical cancer	98	Javanese	Alleles	T: 0.643 (0.429–0.964)	[42]
LMP7	LMP7-145 (c.145C>A; rs2071543)	Cervical cancer	127	Dutch	Alleles	A: 0.565 (0.346–0.920)	[41]
TAP1	TAP1-333 (c.+1177A>G; rs4148880)	CIN III	114	American	Genotypes	AG/GG: 0.28 (0.10–0.80)	[43]
TAP1	TAP1-637 (A>G; rs1135216)	CIN III	114	American	Genotypes	AG/GG: 0.27 (0.1–0.7)	[43]
TAP2	TAP2-651 (c.+1951C>A; rs4148876)	Cervical cancer	127	Dutch	Alleles	A: 0.481 (0.246–0.942)	[41]
			103	Balinese	Alleles	A: 3.837 (2.379–6.189); 47.2%	[42]
TAP2	TAP2-379 (c.1135G>A; rs4148873)	CIN	616	Caucasian	Alleles	A: 0.5 (0.4–0.8)	[44]
Various APM gene combinations	ERAP1-127(G>C)/ ERAP1-730(C>G)/ TAP2-651(C>A)/ LMP7-145(C>A)	Cervical cancer	127	Dutch	Haplotypes	C/G/C/C: 3.024 (1.656–5.519); 11.6%	[41]
	ERAP1-575(C>T)/ TAP2-379(G>A)/ TAP2-651(C>A)	Cervical cancer	98	Javanese	Haplotypes	T/C/G: 3.36 (0.98–11.56); 3.9%	[42]
	ERAP1-56(G>A)/ ERAP1-127 (G>C)	Cervical cancer survival	75	Dutch	Haplotypes	G/C heterozygotes: 0.219 (0.065–0.731)e	[45]

n: number of cases; OR: odds ratio; 95% CI: 95% confidence interval; CIN: cervical intraepithelial neoplasia; PAF: population attributable fraction.

^aNucleotide variation and dbSNP reference number.

^bOR relative to major allele or major allele homozygotes.

^cPAF listed if OR > 1.00.

^dSignificant associations listed in bold.

^eHazard ratio listed for survival analysis.